Compliance Management White Papers & Case Studies

  1. Improve Accuracy And Efficiency In Data Collection For Mental-Health Evaluations And Assessments 5/29/2013

    MedAvante is a global provider of centralized, expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries.

  2. Selecting, Implementing, And Using FDA Compliance Software Solutions 2/28/2013

    We begin by asking the question, “Is the Quality Management Software market evolving to be easier, or more complex?”

  3. Sustainable New Product Innovation With PLM Software 7/15/2011

    Siemens PLM Software’s product lifecycle management (PLM) platform helps transform the process of innovation that enables you to turn more ideas into successful and sustainable products. By Siemens Industry, Inc.

  4. White Paper: Selecting the Right Strategy And Solutions For Pharmaceutical Compliance Management 6/3/2011
    The Pharmaceutical promotional marketplace has undergone massive change over the course of the past decade, driven by the pressures that the Compliance Age has brought to bear. By PharmaTouch
  5. White Paper: Failing To Establish And Maintain CAPA Systems? Your Company Could Be At Risk 10/20/2010
    The pharmaceutical industry has managed its business in much the same way for decades, focusing most of their resources on the next blockbuster drug.By Compliance Implementation Services (CIS)
  6. Sparta Systems Success Story: Invacare Streamlines Complaint Management To Improve Customer Service Levels Worldwide 7/28/2010
    Sparta Systems TrackWise solution enables Invacare to harmonize the complaint intake and investigation process globally, consolidating redundant systems, reducing manual operations, and reducing costs. By Sparta Systems, Inc.
  7. Serialization And The Drug Quality & Security Act: A Top-Down Synergistic Approach

    By Mike Salinas, M&W Group, and David DeJean, Systech International

    Hang around pharmaceutical drug manufacturers long enough and the conversation will undoubtedly turn to the global dilemma of safeguarding the public from the proliferation of counterfeit drugs, and the Drug Quality and Security Act (DQSA).